That's not true. if you miss a move there are still other great companies out there that are just as good to buy. If you bought at 88. then you have had at least 3 chances this year to lower that average. I would rather have a company in which I don't have a full position that is running really well. I can always put the rest of that money into another Biotech that is great like GILD, REGN, ALXN.
"never buy unless you can lower your average"
So if I bought 25 shares at 88.75 and sat and watched it rise that would be awful advice. When it rises enough, buy more and watch where your breakeven point is. 25 shares won't get you anywhere, you have to add as it goes.
gild presents good entry point?
=== Trading at 11.5 times forward earnings, Gilead doesn't look too pricey, despite touching a new high earlier this week. That multiple is below many of its peers, and while some discount is warranted given the uncertain outcome of many of its drugs, it seems too cheap given that on average analysts expect the company to log long-term EPS growth approaching 20%. Gilead also repurchased $1.7 billion of its stock in the quarter.
Gilead is a volatile stock, and like many biotechs, it took investors on a wild ride in 2014. Yet for those willing to stick it out, today's drop looks like a good entry point.
if you do it correctly, it matters little. REGN much like CELG is good long term buy. if you like the company just buy in 25% amounts to lower your average. I do that all the time. I buy a bit just to have some exposure to a company I like. Then I wait for better opportunities to lower my dollar cost average. Just never buy unless you can lower your average. Don't pay up.
just did some research on regn
next downside support is 322
if not hold the next support is
in the arena 295-305 = nice entry point
i dont follow biotech very closely
played biib and gild earning reports
you tell me when will be a good
price to plow in regn (i like it alot)
yes I had sold some at 400. I am waiting for it to come back down to buy it back. It is just a technical correction. REGN just got ahead of itself on valuation basis.
Their net income margin is 51%. That is why I used 50% to be conservative on EPS. I think GED-301 will be closer to 5B in sales but not sure that will fully occur before 2020.
Could be the GILD numbers last night. Sovaldi was expected to slow down since the company was waiting for the approval of Harvoni, the all in one pill sovaldi. I expect the GILD shares (down about 3.50 per share off all time high 113+ yesterday) to recover by Friday. I have been watching CELG - you have to love the numbers. If the market takes a dive in the next few months they are on my short list.